Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, ...

Fintel reports that on March 4, 2025, Leerink Partners downgraded their outlook for Lexicon Pharmaceuticals (NasdaqGS:LXRX) ...

A live audio webcast of the fireside chat can be accessed through the Investors section of the Company’s website at www.mereobiopharma.com/investors. An archived replay of the webcast will be ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by research analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a report released on Monday, ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...

China imposed an import ban on Illumina’s gene sequencers in response to President Trump’s escalating tariffs and trade war ...

ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care ...

Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective decreased by Bank of America from $13.00 to $11.00 in ...

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) Q4 2024 Earnings Call Transcript March 4, 2025 Amylyx Pharmaceuticals, Inc.

Active leads BNP Paribas, Citigroup, JP Morgan, Bank of America, Morgan Stanley and Rabobank set IPTs for the two, three, five, seven, 10, 20, 30 and 40-year tranches at Treasuries plus 75bp area, ...